Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer
|ClinicalTrials.gov Identifier: NCT01815515|
Recruitment Status : Active, not recruiting
First Posted : March 21, 2013
Last Update Posted : April 25, 2017
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Prostate Cancer||Drug: 18F-DCFBC||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||19 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer.|
|Study Start Date :||March 2013|
|Estimated Primary Completion Date :||November 2017|
|Estimated Study Completion Date :||November 2017|
Other Name: A bolus of 10 mCi (370 MBq) [9-11 mCi (333-407 MBq)] of 18F-DCFBC will be injected into the IV line by slow IV push.
- PET/CT detection of Metastatic Prostate Cancer [ Time Frame: 24 Months ]To compare the diagnostic accuracy of DCFBC PET to CIM (CT and bone scintigraphy) for detection of metastatic prostate cancer based on comparison to dynamic CIM incorporating prior and follow-up scans..
- Measurement of new or progressive disease [ Time Frame: 24 Months ]Estimate the proportion of new or progressive metastatic lesions found on conventional imaging modalities (CIM) that are DCFBC PET positive. Estimate the proportion of DCFBC PET positive sites that are positive for new or progressive metastatic disease by conventional imaging modalities (CIM) for prostate cancer.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01815515
|United States, Maryland|
|Johns Hopkins University|
|Baltimore, Maryland, United States, 21287|
|Principal Investigator:||Steve Y Cho, M.D||Johns Hopkins University|